Two Federal IDR Entities Denied Recertification: What Providers Should Know

What did the federal government decide?

On November 4, 2026, the Departments of Health and Human Services, Labor, and the Treasury denied recertification to Island Peer Review Organization, Inc., doing business as IPRO, and Network Medical Review Company, LLC. CMS says both entities failed to meet minimum performance standards required of certified IDR entities.

Neither entity may accept new disputes. Parties with an open dispute assigned to either organization should expect further guidance from the Departments. The two entities have 30 business days from their written denial notices to request an appeal, and the decisions are not final until that process concludes.

What remains unresolved?

The CMS notice identifies the governing standards and the result, but CMS did not specify which standards each entity failed or publish the underlying findings. Certified entities are evaluated on matters that include timeliness, accuracy, independence, impartiality, conflicts, operational capacity, and regulatory compliance. The public cannot tell from the notice which category drove either decision.

Eight other certified IDR entities have completed public petition periods and remain under recertification review. CMS states that the action involving IPRO and Network Medical Review Company does not change the certification status of any other entity.

For providers, the immediate issue is continuity. Open disputes may contain active offer deadlines, fee records, eligibility submissions, and supporting evidence. Parties need written instructions that preserve those filings and prevent the agency transition from creating a new procedural default.

What did the New York Times report?

The New York Times framed the denials within the broader debate over rising IDR volume, provider success rates, award amounts, and the revenue earned by certified entities. The report states that one of the affected entities selected provider offers in approximately 96.5% of determinations, citing an analysis by Turquoise Health.

That statistic deserves context. A win rate describes which offer was selected. It does not show the payer's offer, whether the payer defaulted, the relationship between each offer and the QPA, the quality of the parties' evidence, the eligibility record, or whether the determination was timely and accurate. CMS has not publicly stated that the reported win rate caused either denial.

Halkovich Law's commentary

Federal oversight of IDR entities is necessary. Providers, plans, patients, and policymakers need confidence that determinations are timely, accurate, independent, and free from conflicts. That oversight should also be transparent enough to distinguish a documented performance failure from disagreement with an entity's outcomes.

A high provider win rate does not prove bias, misconduct, or a performance failure. It may warrant review, but the review must examine the disputes behind the percentage. Payer defaults, nominal offers, offers tied to disputed QPAs, claim selection, provider documentation, eligibility decisions, and case mix can all affect the result.

The Departments should publish a meaningful explanation after the appeal process, subject to legitimate confidentiality limits. At minimum, stakeholders should know whether the problem involved timeliness, accuracy, eligibility review, conflicts, reporting, financial controls, or another certification requirement. A bare conclusion cannot guide the remaining entities or the parties that rely on them.

Oversight must also apply across the system. Entity performance matters. So do payer offer practices, initial payment accuracy, QPA calculation, timely participation, and payment after a determination. Evaluating one part of the process without the others produces an incomplete account of why federal IDR cases end the way they do.

What should providers with affected disputes do now?

1. Identify every affected matter. Run a dispute-level report for cases assigned to IPRO or Network Medical Review Company, including dispute status, service lines, deadlines, fees, and pending submissions.
2. Preserve the complete record. Save the selection notice, portal confirmations, open-negotiation materials, offers, supporting documents, eligibility correspondence, invoices, and payment records.
3. Monitor official instructions. CMS says parties with open disputes should expect further guidance. Do not assume the case must be restarted or submit a duplicate dispute without direction.
4. Calendar both existing and transition dates. Maintain current deadlines unless written agency or entity guidance changes them. Record when every instruction was received.
5. Document transition harm. Track added fees, delay, duplicate work, missed portal access, payment aging, and any claim-specific prejudice caused by reassignment.
6. Escalate unclear cases promptly. Seek written clarification from the federal IDR help channel and claim-specific counsel when eligibility, limitations periods, or payment rights may be affected.

What evidence should regulators publish?

• The performance category or categories that each entity failed.
• The measurement period, threshold, and number of affected disputes.
• Whether the findings involved timeliness, accuracy, eligibility, conflicts, reporting, fees, or another requirement.
• How payer defaults, offer amounts, QPA data, case mix, and incomplete submissions were handled in any outcome analysis.
• The plan for reassignment and deadline protection in open disputes.
• The final result of any appeal and the effective date of each final decision.

Those disclosures would let stakeholders evaluate the action on evidence and would give every remaining certified entity a clearer standard for compliance.

Frequently asked questions

Sources and scope

This article is Halkovich Law's original provider-side commentary on the November 4, 2026 federal notice and New York Times reporting. Statements about entity-specific outcome percentages and business results are attributed to the report. The operative recertification status, appeal rights, effect on new disputes, and instructions for open disputes come from CMS.

This page provides general information, not legal advice about any specific dispute. Providers should evaluate current CMS instructions, their portal record, deadlines, plan, payer, governing law, and case-specific circumstances.